Imatinib interacts with a defined set of drug classes, and is contraindicated in pregnancy and unmonitored hepatic impairment. Screening for these before the first dose prevents almost all serious events.
Interaction classes to screen
| Class | Concern | Action |
|---|---|---|
| Metabolic inhibitors | Raised plasma levels and exaggerated effect | Reduce dose or space administration |
| Metabolic inducers | Reduced exposure and treatment failure | Review response and adjust |
| Same-target agents | Additive pharmacology | Avoid duplicate therapy |
| Agents affecting the same organ system | oedema, nausea, muscle cramps, cytopenias, LFT rise | Monitor and document |
Key takeaways
- Screen every new prescription against the patient's full medicine list.
- Common reactions, oedema, nausea, muscle cramps, cytopenias, LFT rise, are amplified by interacting drugs.
- Document the interaction check in the dispensing record.
- Re-screen whenever another long-term medicine is added.
Monitoring in practice
Most interaction risk is manageable with a scheduled review after the onset window of haematological response within weeks, molecular response over months and one further check at steady state. Patients on multiple chronic medicines benefit from an annual structured medication review.
Imatinib at a glance
| Attribute | Detail |
|---|---|
| Drug class | BCR-ABL tyrosine kinase inhibitor |
| Common brand | Gleevec / Veenat |
| Licensed use | chronic myeloid leukaemia and GIST |
| Available strengths | 100 mg, 400 mg |
| Dosage form | film-coated tablet |
| Typical onset | haematological response within weeks, molecular response over months |
| Duration / dosing interval | 24-hour dosing |
| Storage | below 30 °C, original pack |
